Tigulixostat

Tigulixostat
Clinical data
Other namesLC-350189
Legal status
Legal status
  • Investigational
Identifiers
  • 1-(3-cyano-1-propan-2-ylindol-5-yl)pyrazole-4-carboxylic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC16H14N4O2
Molar mass294.314 g·mol−1
3D model (JSmol)
  • CC(C)N1C=C(C2=C1C=CC(=C2)N3C=C(C=N3)C(=O)O)C#N
  • InChI=1S/C16H14N4O2/c1-10(2)19-8-11(6-17)14-5-13(3-4-15(14)19)20-9-12(7-18-20)16(21)22/h3-5,7-10H,1-2H3,(H,21,22)
  • Key:JLQQRYOWGCIMMZ-UHFFFAOYSA-N

Tigulixostat is an investigational new drug that is being evaluated for the treatment of gout.[1] It is a xanthine oxidase inhibitor.[2]

References

  1. ^ "Tigulixostat - LG Chem". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Yip K, Braverman G, Yue L, Fields T (March 2024). "Pipeline Therapies for Gout". Current Rheumatology Reports. 26 (3): 69–80. doi:10.1007/s11926-023-01128-3. PMID 38133712.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.